- Home
- BLFS vs GHRS Comparison
BLFS vs GHRS Comparison
Compare BLFS & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BLFS | GHRS |
|---|---|---|
| Founded | 1987 | 2018 |
| Country | United States | Ireland |
| Employees | 155 | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 923.5M | 1.0B |
| IPO Year | 2013 | 2021 |
Fundamental Metrics
Financial Performance| Metric | BLFS | GHRS |
|---|---|---|
| Price | $19.27 | $14.71 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | $32.00 | ★ $41.38 |
| AVG Volume (30 Days) | ★ 482.9K | 193.2K |
| Earning Date | 05-07-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 77.27 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $96,214,000.00 | N/A |
| Revenue This Year | $19.73 | N/A |
| Revenue Next Year | $17.82 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 16.97 | N/A |
| 52 Week Low | $17.86 | $7.98 |
| 52 Week High | $29.57 | $19.51 |
Technical Indicators
Market Signals| Indicator | BLFS | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 39.57 | 44.88 |
| Support Level | N/A | $12.04 |
| Resistance Level | $25.95 | $14.80 |
| Average True Range (ATR) | 0.93 | 0.87 |
| MACD | -0.03 | -0.09 |
| Stochastic Oscillator | 23.86 | 17.19 |
Price Performance
Historical ComparisonAbout BLFS BioLife Solutions Inc.
BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.